These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 19378292)

  • 1. Diffusion tensor imaging in a rat model of Parkinson's disease after lesioning of the nigrostriatal tract.
    Van Camp N; Blockx I; Verhoye M; Casteels C; Coun F; Leemans A; Sijbers J; Baekelandt V; Van Laere K; Van der Linden A
    NMR Biomed; 2009 Aug; 22(7):697-706. PubMed ID: 19378292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
    Aponso PM; Faull RL; Connor B
    Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 6-Hydroxydopamine-induced lesions in a rat model of hemi-Parkinson's disease monitored by magnetic resonance imaging.
    Kondoh T; Bannai M; Nishino H; Torii K
    Exp Neurol; 2005 Mar; 192(1):194-202. PubMed ID: 15698634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of unilateral lesion of the nigrostriatal dopamine pathway on survival and neurochemistry of parafascicular nucleus neurons in the rat--evaluation of time-course and LGR8 expression.
    Sedaghat K; Finkelstein DI; Gundlach AL
    Brain Res; 2009 May; 1271():83-94. PubMed ID: 19328193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A proteomic approach in the study of an animal model of Parkinson's disease.
    De Iuliis A; Grigoletto J; Recchia A; Giusti P; Arslan P
    Clin Chim Acta; 2005 Jul; 357(2):202-9. PubMed ID: 15946658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature.
    Péran P; Cherubini A; Assogna F; Piras F; Quattrocchi C; Peppe A; Celsis P; Rascol O; Démonet JF; Stefani A; Pierantozzi M; Pontieri FE; Caltagirone C; Spalletta G; Sabatini U
    Brain; 2010 Nov; 133(11):3423-33. PubMed ID: 20736190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkinson Disease: Diffusion MR Imaging to Detect Nigrostriatal Pathway Loss in a Marmoset Model Treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Hikishima K; Ando K; Yano R; Kawai K; Komaki Y; Inoue T; Itoh T; Yamada M; Momoshima S; Okano HJ; Okano H
    Radiology; 2015 May; 275(2):430-7. PubMed ID: 25602507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo magnetic resonance imaging characterization of bilateral structural changes in experimental Parkinson's disease: a T2 relaxometry study combined with longitudinal diffusion tensor imaging and manganese-enhanced magnetic resonance imaging in the 6-hydroxydopamine rat model.
    Soria G; Aguilar E; Tudela R; Mullol J; Planas AM; Marin C
    Eur J Neurosci; 2011 Apr; 33(8):1551-60. PubMed ID: 21410791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NMDA receptors mediate an early up-regulation of brain-derived neurotrophic factor expression in substantia nigra in a rat model of presymptomatic Parkinson's disease.
    Bustos G; Abarca J; Bustos V; Riquelme E; Noriega V; Moya C; Campusano J
    J Neurosci Res; 2009 Aug; 87(10):2308-18. PubMed ID: 19326433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations of the nigrostriatal pathway in a 6-OHDA rat model of Parkinson's disease evaluated with multimodal MRI.
    Perlbarg V; Lambert J; Butler B; Felfli M; Valabrègue R; Privat AL; Lehéricy S; Petiet A
    PLoS One; 2018; 13(9):e0202597. PubMed ID: 30188909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted overexpression of the parkin substrate Pael-R in the nigrostriatal system of adult rats to model Parkinson's disease.
    Dusonchet J; Bensadoun JC; Schneider BL; Aebischer P
    Neurobiol Dis; 2009 Jul; 35(1):32-41. PubMed ID: 19348945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling nigrostriatal degeneration in organotypic cultures, a new ex vivo model of Parkinson's disease.
    Daviaud N; Garbayo E; Lautram N; Franconi F; Lemaire L; Perez-Pinzon M; Montero-Menei CN
    Neuroscience; 2014 Jan; 256():10-22. PubMed ID: 24161279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of striatonigral connectivity using probabilistic tractography in Parkinson's disease.
    Theisen F; Leda R; Pozorski V; Oh JM; Adluru N; Wong R; Okonkwo O; Dean DC; Bendlin BB; Johnson SC; Alexander AL; Gallagher CL
    Neuroimage Clin; 2017; 16():557-563. PubMed ID: 28971007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRI diffusion in Parkinson's disease: using the technique's inherent directional information to study the olfactory bulb and substantia nigra.
    Skorpil M; Söderlund V; Sundin A; Svenningsson P
    J Parkinsons Dis; 2012; 2(2):171-80. PubMed ID: 23939442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease.
    Zecca L; Wilms H; Geick S; Claasen JH; Brandenburg LO; Holzknecht C; Panizza ML; Zucca FA; Deuschl G; Sievers J; Lucius R
    Acta Neuropathol; 2008 Jul; 116(1):47-55. PubMed ID: 18343932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of onset of Parkinson's disease by in vivo gene transfer of human hepatocyte growth factor in rodent model: a model of gene therapy for Parkinson's disease.
    Koike H; Ishida A; Shimamura M; Mizuno S; Nakamura T; Ogihara T; Kaneda Y; Morishita R
    Gene Ther; 2006 Dec; 13(23):1639-44. PubMed ID: 16791285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-invasive MR imaging of neurodegeneration in a rodent model of Parkinson's disease.
    Vernon AC; Modo M
    Methods Mol Biol; 2011; 711():487-510. PubMed ID: 21279619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Further characterisation of the LPS model of Parkinson's disease: a comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat.
    Hoban DB; Connaughton E; Connaughton C; Hogan G; Thornton C; Mulcahy P; Moloney TC; Dowd E
    Brain Behav Immun; 2013 Jan; 27(1):91-100. PubMed ID: 23044176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model.
    Blandini F; Levandis G; Bazzini E; Nappi G; Armentero MT
    Eur J Neurosci; 2007 Jan; 25(2):397-405. PubMed ID: 17284180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time-dependent alterations of peripheral immune parameters after nigrostriatal dopamine depletion in a rat model of Parkinson's disease.
    Engler H; Doenlen R; Riether C; Engler A; Niemi MB; Besedovsky HO; del Rey A; Pacheco-López G; Feldon J; Schedlowski M
    Brain Behav Immun; 2009 May; 23(4):518-26. PubMed ID: 19486644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.